文献库 文献相关信息

题目:
Cytotoxic human peripheral blood-derived γδT cells kill glioblastoma cell lines: implications for cell-based immunotherapy for patients with glioblastoma.
作者:
Nakazawa(Tsutomu),Nakamura(Mitsutoshi),Park(Young Soo),Motoyama(Yasushi),Hironaka(Yasuo),Nishimura(Fumihiko),Nakagawa(Ichiro),Yamada(Shuichi),Matsuda(Ryosuke),Tamura(Kentaro),Sugimoto(Tadashi),Takeshima(Yasuhiro),Marutani(Akiko),Tsujimura(Takahiro),Ouji(Noriko),Ouji(Yukiteru),Yoshikawa(Masahide),Nakase(Hiroyuki)
状态:
发布时间2013-12-24 , 更新时间 2014-11-20
期刊:
J Neurooncol
摘要:
Glioblastoma (GBM) is a highly aggressive brain tumor for which novel therapeutic approaches, such as immunotherapy, are urgently needed. Zoledronate (ZOL), an inhibitor of osteoclastic activity, is known to stimulate peripheral blood-derived γδT cells and sensitize tumors to γδT cell-mediated killing. To investigate the feasibility of γδT cell-based immunotherapy for patients with GBM, we focused on the killing of GBM cell lines by γδT cells and the molecular mechanisms involved in these cell-cell interactions. Peripheral blood mononuclear cells were expanded in ZOL and interleukin (IL)-2 for 14 days, and γδT cells were enriched in the expanded cells by the immunomagnetic depletion of αβT cells. Gliomas are resistant to NK cells but susceptible to lymphokine-activated killer cells and some cytotoxic T lymphocytes. When the γδT cell-mediated killing of three GBM cell lines (U87MG, U138MG and A172 cells) and an NK-sensitive leukemia cell line (K562 cells) were tested, 32% U87MG, 15% U138MG, 1% A172, and 50% K562 cells were killed at an effector:target ratio of 5:1. The γδT cell-mediated killing of all three GBM cell lines was significantly enhanced by ZOL and this ZOL-enhanced killing was blocked by an anti-T cell receptor (TcR) antibody. These results indicated that TcR γδ is crucial for the recognition of ZOL-treated GBM cells by γδT cells. Since the low level killing of GBM cells by the γδT cells was enhanced by ZOL, γδT cell-targeting therapy in combination with ZOL treatment could be effective for patients with GBM.
语言:
eng
DOI:
10.1007/s11060-013-1258-4

联系方式

山东省济南市章丘区文博路2号 齐鲁师范学院 genelibs生信实验室

山东省济南市高新区舜华路750号大学科技园北区F座4单元2楼

电话: 0531-88819269

E-mail: product@genelibs.com

微信公众号

关注微信订阅号,实时查看信息,关注医学生物学动态。